Conquest Research News Today

BOSTON — Treatment with LX9211 reduced pain related to postherpetic neuralgia and may be a valuable addition to current options for peripheral neuropathic pain, according to a presenter at the American Academy of Neurology annual meeting.“LX9211 is a nonopioid, oral medication designed to exert minimal effects by limiting activity of the [adapter protein-2 associated kinase 1

Phase II study misses primary endpoint, but likely to move forward anyway

Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer's disease (AD) patientsTB006 also demonstrated

TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference GlobeNewswire December 06, 2022 Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2...

Conference Call and Webcast at 5:00pm ET on November 14, 2022, Following the Oral Presentation...